Better Therapeutics, Inc. (BTTX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 10.34 Million USD | 8.87% |
| 2021 | 9.5 Million USD | 1385.16% |
| 2020 | 640 Thousand USD | -87.2% |
| 2019 | 5 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | 9 Million USD | -13.02% |
| 2023 Q2 | 8.51 Million USD | -5.35% |
| 2023 Q3 | 7.72 Million USD | -9.37% |
| 2022 Q3 | 11.65 Million USD | -9.69% |
| 2022 Q2 | 12.9 Million USD | 38.81% |
| 2022 Q1 | 9.29 Million USD | -2.17% |
| 2022 FY | 10.34 Million USD | 8.87% |
| 2022 Q4 | 10.34 Million USD | -11.23% |
| 2021 FY | 9.5 Million USD | 1385.16% |
| 2021 Q4 | 9.5 Million USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | -100.0% |
| 2021 Q1 | 640.00 USD | 0.0% |
| 2020 Q4 | 640.00 USD | 0.0% |
| 2020 FY | 640 Thousand USD | -87.2% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | 5 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -821.347% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -700.929% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 76.34% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -103380.0% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -7508.824% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -8501.686% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -19.052% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 78.829% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -176.408% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 63.567% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 93.149% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -4625.136% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -1035.272% |
| Molecular Templates, Inc. | 9.74 Million USD | -6.22% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -452.862% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 45.728% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -146.733% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 90.082% |
| Statera Biopharma, Inc. | 11.43 Million USD | 9.475% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -1313.661% |
| Trevena, Inc. | 35.23 Million USD | 70.63% |
| Vaxxinity, Inc. | 13.26 Million USD | 21.973% |
| Vaccinex, Inc. | 26 Thousand USD | -39700.0% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |